Stackline and Redslim Partner to Deliver Unparalleled Retail Intelligence and Data Integration for Global Brands
19.3.2025 14:00:00 CET | Business Wire | Press release
Stackline, the leader in retail intelligence and data-driven commerce solutions, has announced a strategic partnership with Redslim, a leading data management company specializing in optimizing syndicated market data. This collaboration provides global CPG and CHC brands with a high-fidelity, 360-degree view of category performance—equipping them to make smarter, faster decisions in an increasingly competitive marketplace.
Stackline’s industry-leading solutions provide brands and manufacturers with deep, data-driven insights into category performance. By tracking sales volume, traffic, and conversion rates across the world’s top retail ecosystems, including Amazon, Stackline enables brands to decode the omnichannel shopper journey with precision. Its digital shelf solution delivers advanced analytics to optimize product listings, enhance digital shelf performance, and drive sustained ecommerce growth.
Redslim specializes in transforming fragmented market measurement data into harmonized, ready-to-use datasets. By integrating siloed data sources into centralized analytics systems, Redslim enables businesses to unlock actionable insights on market share, marketing effectiveness, and innovation strategies. This holistic approach ensures brands can leverage their data as a strategic asset, enabling smarter decisions and sustained competitive advantage.
This partnership between Stackline and Redslim fundamentally reshapes how brands harness data, seamlessly integrating Stackline’s intelligence into centralized analytics ecosystems. By unifying online and offline data, brands gain a comprehensive, end-to-end solution for optimizing performance and driving growth. With coverage across North America, Europe, and Asia—where a single marketplace can account for up to 20% of total market share—this collaboration delivers unparalleled visibility into online and omnichannel dynamics.
“Our partnership with Redslim strengthens our ability to deliver unmatched data access and actionable insights,” said Mitch Keidan, Vice President of Strategic Partnerships at Stackline. “By embedding Stackline’s intelligence into Redslim’s systems, we’re unlocking new ways for brands to maximize their data’s potential and fuel smarter, faster decisions.”
Marta Battiston, Chief Strategy Officer at Redslim, added, “By integrating Redslim’s harmonized syndicated market data with Stackline’s omnichannel and retail intelligence, we’re bridging critical data gaps and empowering brands with a truly comprehensive solution for strategic decision-making.”
As digital commerce continues to evolve, the ability to synthesize and interpret ecommerce and omnichannel data is more crucial than ever. Together, Stackline and Redslim are delivering an all-encompassing solution that enables brands to access harmonized market data, gain deeper ecommerce insights, and achieve a holistic view of market performance and competitive intelligence.
About Redslim
Redslim streamlines data management for teams faced with the request to leverage fragmented datasets for critical decision-making. Specialized in data engineering, harmonization, and BI, their teams manage data from over 50 agencies and cover more than 55 countries. Their technology-enabled services optimize data consumption for more than 30 global organizations. Active for more than 10 years, Redslim has constantly innovated their solutions to always meet the evolving needs of their clients and data partners. Learn more at www.redslim.net and follow Redslim on LinkedIn.
About Stackline
On a mission to fuel the future of commerce by bringing brands and customers closer together, Stackline is the leading AI-enabled retail intelligence and activation platform for the world's most innovative brands. Business leaders, product innovators, performance marketers, and financial firms trust Stackline as the single source of commerce truth. Fueled by proprietary neural networks and deep learning systems, Stackline's market insights, revenue metrics, behavioral data, and autonomous functionality create the actions that determine success or failure. Founded in 2014 in Seattle, Stackline employs over 250 connected commerce professionals creating value for 7,000 global brands.
Learn more by visiting https://www.stackline.com/partners or contact media@stackline.com. Follow Stackline on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250319045474/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom